Afinum 2017 Buyout (ZABWDX) News

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form S-3 - Registration statement under Securities Act of 1933

Form PRE 14A - Other preliminary proxy statements

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

KANSAS CITY, Kan., June 28, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (the “Company”) (NASDAQ: CING), a...

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical...

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Twelve Required Registration Batches CompletedNew Drug Application Being Prepped for Submission KANSAS CITY...

FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD

Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application        CTx-1301 Could Benefit...

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

CTx-1301 on track to file for Marketing Approval with FDA in 1H 2025 Increase of $10 Million in Stockholders’...

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

KANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical...

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

KANSAS CITY, Kan., April 16, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical...

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

$17.8 Million Raised Since Beginning of 2023$9.1 Million of Debt Converted to Equity at a PremiumPhase 3 ADHD...

Cingulate to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., March 19, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical...

Form 4 - Statement of changes in beneficial ownership of securities